journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Neurotherapeutics

journal
https://www.readbyqxmd.com/read/28548894/switching-from-an-oral-dopamine-receptor-agonist-to-rotigotine-transdermal-patch-a-review-of-clinical-data-with-a-focus-on-patient-perspective
#1
Sun Ju Chung, Mahnaz Asgharnejad, Lars Bauer, Arturo Benitez, Babak Boroojerdi, Tanja Heidbrede, Allison Little, Han Joon Kim
Dopamine receptor agonists (DAs) are commonly used to treat Parkinson's disease (PD) and restless legs syndrome (RLS). In certain situations, switching from oral DAs to rotigotine transdermal patch may be beneficial for the patient (e.g., optimal symptom control/side effects/perioperative management, preference for once-daily/non-oral administration, RLS augmentation treatment). Areas covered: This narrative review summarizes available data on DA dose equivalency, dose conversions, switching schedules, safety, tolerability, efficacy and patient treatment preferences of switching from oral DAs to rotigotine (and vice versa) in patients with PD/RLS...
May 26, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28548892/immune-related-neurological-toxicities-among-solid-tumor-patients-treated-with-immune-checkpoint-inhibitors-a-systematic-review
#2
Mostafa Eltobgy, Hani Oweira, Ulf Petrausch, Daniel Helbling, Jan Schmidt, Arianeb Mehrabi, Othmar Schöb, Anwar Giryes, Michael Decker, Omar Abdel-Rahman
Immune-related neurologic toxicities are uncommon but serious adverse events that may be associated with the use of immune checkpoint inhibitors. The objective of this review is to assess the incidence and risk of neurologic toxicities which are potentially immune-related and occur with immune checkpoint treatment of solid tumors. Areas covered: PubMed database has been searched till January 2017. Clinical trials, case series and case reports reporting the occurrence of immune-related neurologic toxicities in solid tumor patients treated with immune checkpoint inhibitors were included...
May 26, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28532252/chronic-subthreshold-cortical-stimulation-a-therapeutic-and-potentially-restorative-therapy-for-focal-epilepsy
#3
Brian Nils Lundstrom, Gregory A Worrell, Matt Stead, Jamie J Van Gompel
Approximately one third of patients with focal epilepsy continue to have ongoing seizures despite adequate trials of anti-seizure medications. Surgery to remove the epileptogenic zone remains the most efficacious treatment option for focal drug-resistant epilepsy. However, when cortical areas are eloquent or there are multiple epileptogenic zones, surgical resection is not an ideal approach. Cortical stimulation provides an attractive alternative. Area Covered: Here, the authors describe Chronic Subthreshold Cortical Stimulation (CSCS), which uses continuous intracranial electrical stimulation applied near the epileptogenic zone to lower seizure probability...
May 22, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28490214/emerging-amyloid-and-tau-targeting-treatments-for-alzheimer-s-disease
#4
Ayesha Khan, Anne Corbett, Clive Ballard
With an ageing global population, the number of people with dementia, and its main cause Alzheimer's disease (AD), is growing. current licensed treatments available for ad are only alleviate the symptoms of the disease, and are effective only in some people with ad for a limited time. there are currently no therapies that target the disease process. Areas covered: This review summarizes the available treatments for AD and the emerging therapies in the clinical trials pipeline. There are ongoing trials at various stages of development, targeting different mechanisms and pathways implicated in the disease...
May 19, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28521561/late-onset-seizures-a-subclinical-cerebrovascular-disorder
#5
Francesco Brigo, Raffaele Nardone
No abstract text is available yet for this article.
May 18, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28511562/a-review-of-cognitive-remediation-approaches-for-schizophrenia-from-top-down-to-bottom-up-brain-training-to-psychotherapy
#6
Michael W Best, Christopher R Bowie
Individuals with psychotic disorders experience profound impairment in neurocognition, which is consistently found to be the best predictor of independent community functioning. Several diverse behavioural treatments designed to enhance neurocognitive abilities have been developed, with subtle to stark differences among them. Various approaches, to varying degrees, have demonstrated success across diffuse outcomes: improved brain structure and function, performance on neuropsychological tests, and community activities associated with daily living...
May 16, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28490260/emerging-treatments-for-alzheimer-s-disease-for-non-amyloid-and-non-tau-targets
#7
Ayesha Khan, Anne Corbett, Clive Ballard
The number of people with dementia, including Alzheimer's disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, and despite research efforts, the underlying mechanisms of AD and optimal treatment targets have not been fully elucidated. Amyloid and tau are key pathological markers of AD with ongoing trials targeting both...
May 11, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28471250/primary-care-doctors-should-not-screen-their-patients-for-depression
#8
Brett D Thombs, Roy C Ziegelstein
No abstract text is available yet for this article.
May 4, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28468528/improving-physical-health-of-patients-with-severe-mental-disorders-a-critical-review-of-lifestyle-psychosocial-interventions
#9
Corrado De Rosa, Gaia Sampogna, Mario Luciano, Valeria Del Vecchio, Benedetta Pocai, Giuseppina Borriello, Vincenzo Giallonardo, Micaela Savorani, Federica Pinna, Maurizio Pompili, Andrea Fiorillo
People with severe mental disorders have a mortality rate that is more than two times higher than the general population, with at least a decade of potential years of life lost. People with mental disorders have a significantly higher risk of obesity, hyperglycemia and metabolic syndrome, which are related to modifiable risk factors, such as heavy smoking, poor physical activities, and inappropriate unhealthy diet, which can be improved through lifestyle changes. Areas covered: Lifestyle behaviours are amenable to change through the adoption of specific psychosocial interventions, and several approaches have been promoted...
May 3, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28460553/how-should-we-treat-post-traumatic-stress-disorder-in-active-military-personnel
#10
Kirsten H Dillon, Stefanie T LoSavio, Patricia A Resick
No abstract text is available yet for this article.
May 2, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28293960/moving-forward-how-depression-heterogeneity-hinders-progress-in-treatment-and-research
#11
E I Fried
No abstract text is available yet for this article.
March 22, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28277802/oxycodone-extended-release-capsules-for-the-treatment-of-chronic-pain
#12
Sebastiano Mercadante
As a consequence of greater prescription opioid utilization, there has been the parallel increase in misuse, abuse, and overdose, which are serious risks. Associated new formulations may be safer. Areas covered: The introduction of abuse-deterrent opioid formulations and continuous programs to improve opioid prescribing practices may limit the opioid abuse and its consequences. Oxycodone extended release capsules are an extended-release (ER), microsphere-in-capsule abuse-deterrent-formulation designed to retain its extended-release properties following tampering or misuse (e...
March 10, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28406336/intrajejunal-levodopa-infusion-therapy-for-parkinson-s-disease-practical-and-pragmatic-tips-for-successful-maintenance-of-therapy
#13
Nataliya Titova, K Ray Chaudhuri
Intrajejunal levodopa infusion (IJLI) therapy is one of the most influential therapies in moderate to late stage Parkinson's disease with documented effects on motor and nonmotor symptoms and quality of life. The process of initiation and maintenance of therapy however, remains a challenge particularly in the long term. Areas covered: The authors reviewed 'evidence base' for pathways and advice given to patients pre and post IJLI initiation. The authors found lack of patient, carer and clinician led 'real life' advisory documents which need to be given to patients on IJLI...
June 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28374628/birth-control-in-epilepsy-we-need-to-know-more
#14
Anne Davis, Alison Pack, Dale Hesdorffer, Page Pennell
No abstract text is available yet for this article.
June 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28359202/response-to-birth-control-in-epilepsy-we-need-to-know-more
#15
Doodipala Samba Reddy
No abstract text is available yet for this article.
June 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28343407/what-are-the-complications-and-emerging-strategies-for-preventing-depression-following-traumatic-brain-injury
#16
Melissa Jones, Laura Acion, Ricardo E Jorge
Depression is a common and disabling complication of traumatic brain injury (TBI). The high rates of post-TBI depression (PTBID) make this condition an important candidate for selective preventive interventions. Areas covered: The authors recently reported on the efficacy of sertraline, a selective serotonin reuptake inhibitor (SSRI), for the prevention of new cases of depression in the first six months after TBI. The authors review this and other studies on preventive strategies in PTBID as ascertained from a PubMed and citation search...
June 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28335645/treatment-of-sleep-disorders-in-youth-with-adhd-what-is-the-evidence-from-randomised-controlled-trials-and-how-should-the-field-move-forward
#17
Samuele Cortese, Marco Angriman
No abstract text is available yet for this article.
June 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28128996/endogenous-repair-and-development-inspired-therapy-of-neurodegeneration-in-progressive-multiple-sclerosis
#18
Ethan Hollingsworth, Jamil Khouri, Jaime Imitola
In recent years, there has been progress in understanding the etiology and immune mechanisms of multiple sclerosis (MS). however, for most, once the diagnosis is made, significant pathology is already present in the central nervous system (CNS), and in many, this leads to neurodegeneration, which accumulates in disability. although, the mechanisms of such progression are poorly understood, new data suggest lack of remyelination paired with dysfunction of neurons along with stem and progenitor cells as the basis and recent developmental studies suggest that cns repair processes share mechanisms with development...
June 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28092989/therapeutic-complement-inhibition-a-promising-approach-for-treatment-of-neuroimmunological-diseases
#19
Kjara S Pilch, Peter J Spaeth, Nobuhiro Yuki, Benjamin R Wakerley
Autoimmunity is an important cause of disease both in the central and peripheral nervous systems. Aetiologies and clinical manifestations are complex and heterogeneous. Inappropriate control of complement activation at inappropriate sites has been recognized as a major determinant in several neurological conditions, including Guillain-Barré syndrome and neuromyelitis optica. In each case pathogenesis is thought to be associated with generation of autoantibodies which upon binding guide activation of the complement system to self-tissue...
June 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28092469/investigational-drugs-in-recent-clinical-trials-for-treatment-resistant-depression
#20
Ricardo P Garay, Carlos A Zarate, Thomas Charpeaud, Leslie Citrome, Christoph U Correll, Ahcène Hameg, Pierre-Michel Llorca
The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future. Areas covered: Sixty-two trials were identified in US and EU clinical trial registries that included six investigational compounds in recent phase III development and 12 others in recent phase II clinical trials. Glutamatergic agents have been the focus of many studies. A single intravenous dose of the glutamatergic modulator ketamine produces a robust and rapid antidepressant effect in persons with TRD; this effect continues to remain significant for 1 week...
June 2017: Expert Review of Neurotherapeutics
journal
journal
39882
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"